Peptides vs. approved GLP-1s: sorting hype from clinical fact

What did @teamcoachgab actually say?

The honest answer here is: we genuinely cannot tell. The transcript provided is almost certainly a failed auto-transcription of a French-language video, producing word salad like "it's not a bad way to get the next son" and references to "$1 per year" that have nothing to do with peptides. What we do have is the caption, which is clear enough. @teamcoachgab says they are calling out influencers who push peptides like BPC-157, Mots-C, and Tesamorelin for physical results, while acknowledging that some peptides, specifically insulin, osteoporosis treatments, and semaglutide (Ozempic), have legitimate therapeutic approval. That framing alone is more nuanced than most fitness TikTok content on this subject.

So this fact-check will work from the caption's explicit claims, because the transcript is not usable source material.

Does the science back this up?

On the core distinction between approved and unapproved peptides, yes, the science is firmly on the creator's side. The peptides they single out for criticism are all research compounds without current human-use approval from Health Canada, the FDA, or the EMA.

BPC-157 (Body Protection Compound-157) is a synthetic peptide derived from a gastric protein. Rat studies have shown tissue-healing effects (Sikiric et al., 2018, Current Pharmaceutical Design), but no phase III human clinical trial data exists. Its mechanism in humans is unconfirmed, and it is not approved anywhere for human use.

Mots-C is a mitochondria-derived peptide with early metabolic research interest (Lee et al., 2015, Cell Metabolism), but again, human trial evidence is extremely limited and it carries no regulatory approval.

Tesamorelin is a partial exception worth noting. It is FDA-approved under the brand name Egrifta for HIV-associated lipodystrophy. But its off-label use for general fat loss or growth hormone secretion in healthy adults is not supported by sufficient evidence, and sourcing it outside a supervised prescription context is legally and medically problematic.

What did they get wrong (or right)?

@teamcoachgab gets meaningful credit for correctly identifying that regulatory approval is a meaningful line, not a technicality. That distinction matters a lot in a space where influencers routinely treat "peptide" as a synonym for "safe because natural."

The grouping of Tesamorelin with BPC-157 and Mots-C is slightly imprecise, since Tesamorelin does have one approved indication. A more rigorous take would have separated "approved for a narrow population, not for gym use" from "no human approval at all." That is a real difference.

The caption's framing also implies that unapproved peptides are primarily a credibility or regulatory problem. That understates the safety concern. Unregulated peptides sold online frequently fail purity and concentration testing. A 2022 study by Svendsen et al. in Drug Testing and Analysis found significant labeling inaccuracies in peptide products purchased from online sources, including wrong concentrations and contaminants. The risk is not just "it might not work." It is "you do not know what you are injecting."

What should you actually know?

The peptide supplement market operates in a regulatory gray zone that benefits sellers, not buyers. Compounds labeled "for research use only" are legally sold in many jurisdictions but routinely purchased by people intending to self-inject. This is not a minor loophole. It means zero quality oversight, no standardized dosing, and no post-market safety surveillance.

For GLP-1 medications like semaglutide, the regulatory line is the opposite problem: these are approved drugs with real evidence behind them, but compounded versions have flooded the market during shortage periods. The FDA has explicitly warned that compounded semaglutide is not equivalent to Ozempic or Wegovy, and product quality cannot be assumed.

If you are seeing peptide content on fitness TikTok, the question to ask is not "does this peptide do something interesting in rats?" Many of them do. The question is whether there is human trial evidence for the specific outcome being claimed, at a dose and delivery method that is actually reproducible and safe. For BPC-157 and Mots-C, that evidence does not currently exist. For Tesamorelin outside its approved use, the answer is the same.

Anyone seriously considering peptide therapy should be working with a licensed clinician who can review their health history, not following a protocol sourced from a TikTok comment section.